Form 8-K

8-K — PALVELLA THERAPEUTICS, INC.

Accession: 0001193125-26-210605

Filed: 2026-05-07

Period: 2026-05-07

CIK: 0001583648

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — pvla-20260507.htm (Primary)

EX-99.1 (pvla-ex99_1.htm)

EX-99.2 (pvla-ex99_2.htm)

GRAPHIC (img6060170_0.jpg)

GRAPHIC (pvla-ex99_2s1.jpg)

GRAPHIC (pvla-ex99_2s2.jpg)

GRAPHIC (pvla-ex99_2s3.jpg)

GRAPHIC (pvla-ex99_2s4.jpg)

GRAPHIC (pvla-ex99_2s5.jpg)

GRAPHIC (pvla-ex99_2s6.jpg)

GRAPHIC (pvla-ex99_2s7.jpg)

GRAPHIC (pvla-ex99_2s8.jpg)

GRAPHIC (pvla-ex99_2s9.jpg)

GRAPHIC (pvla-ex99_2s10.jpg)

GRAPHIC (pvla-ex99_2s11.jpg)

GRAPHIC (pvla-ex99_2s12.jpg)

GRAPHIC (pvla-ex99_2s13.jpg)

GRAPHIC (pvla-ex99_2s14.jpg)

GRAPHIC (pvla-ex99_2s15.jpg)

GRAPHIC (pvla-ex99_2s16.jpg)

GRAPHIC (pvla-ex99_2s17.jpg)

GRAPHIC (pvla-ex99_2s18.jpg)

GRAPHIC (pvla-ex99_2s19.jpg)

GRAPHIC (pvla-ex99_2s20.jpg)

GRAPHIC (pvla-ex99_2s21.jpg)

GRAPHIC (pvla-ex99_2s22.jpg)

GRAPHIC (pvla-ex99_2s23.jpg)

GRAPHIC (pvla-ex99_2s24.jpg)

GRAPHIC (pvla-ex99_2s25.jpg)

GRAPHIC (pvla-ex99_2s26.jpg)

GRAPHIC (pvla-ex99_2s27.jpg)

GRAPHIC (pvla-ex99_2s28.jpg)

GRAPHIC (pvla-ex99_2s29.jpg)

GRAPHIC (pvla-ex99_2s30.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: pvla-20260507.htm · Sequence: 1

8-K

0001583648false00015836482026-05-072026-05-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 7, 2026

Palvella Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Nevada

001-37471

30-0784346

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

353 W. Lancaster Ave, Suite 200

Wayne, Pennsylvania

19087

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (484) 253-1461

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

PVLA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 7, 2026, Palvella Therapeutics, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 7.01 Regulation FD Disclosure.

On May 7, 2026, the Company will hold its earnings call and use a slide presentation in conjunction with the earnings call. A copy of the presentation is furnished herewith as Exhibit 99.2, and incorporated herein by reference.

The information furnished pursuant to Item 7.01, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release of Palvella Therapeutics, Inc., dated May 7, 2026*

99.2

Earnings Call Presentation of Palvella Therapeutics, Inc., dated May 7, 2026*

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Palvella Therapeutics, Inc.

Date:

May 7, 2026

By:

/s/ Matthew Korenberg

Matthew Korenberg

Chief Financial Officer

EX-99.1

Filename: pvla-ex99_1.htm · Sequence: 2

EX-99.1

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

FDA Pre-New Drug Application (NDA) meeting granted for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, with meeting expected in second quarter of 2026; NDA submission on track for second half of 2026

Accelerating U.S. launch readiness for QTORIN™ rapamycin for microcystic lymphatic malformations; BEYONDmLM.com disease awareness campaign launched to educate, engage, and empower patients, caregivers, and healthcare professionals

Initiation of Phase 3 trial of QTORIN™ rapamycin for the treatment of cutaneous venous malformations planned for second half of 2026

Initiation of Phase 2 trial of QTORIN™ pitavastatin for the treatment of disseminated superficial actinic porokeratosis planned for second half of 2026

Phase 2 LOTU trial of QTORIN™ rapamycin for clinically significant angiokeratomas initiated with topline results expected in second half of 2027

Completed upsized, oversubscribed equity financing of $230.0 million in February 2026; cash, cash equivalents and short-term investments of $261.9 million as of March 31, 2026

Company to host conference call at 8:30 a.m. ET today

WAYNE, PA., May 7, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today reported financial results for the first quarter ending March 31, 2026 and provided a corporate update.

“Following the positive Phase 3 SELVA topline results, we believe Palvella is on a clear path toward near-term NDA submission for QTORIN™ rapamycin in microcystic lymphatic malformations, with the potential for approval and U.S. commercial launch in the first half of 2027,” said Wes Kaupinen, Founder and Chief Executive Officer of Palvella. “Our $230.0 million financing with participation from high-quality new and existing investors meaningfully strengthens our balance sheet, which supports our plan for U.S. commercialization, and enables us to attract key talent as we prepare for a potential first-in-disease launch. At the same time, we continue to rapidly advance our pipeline beyond microcystic LMs, with the goal of expanding our QTORIN™-derived programs across six serious, rare skin diseases and vascular malformations by year-end.”

Recent Research and Development Highlights

QTORIN™ rapamycin for microcystic lymphatic malformations (microcystic LMs)

•

Reported positive topline data from the Phase 3 SELVA study demonstrating statistically significant results across the primary and all pre-specified secondary endpoints.

•

In collaboration with leading nonprofit and advocacy organizations, launched the “BEYOND mLM” disease awareness campaign and BEYONDmLM.com to educate and engage patients, caregivers, and healthcare professionals on microcystic lymphatic malformations.

•

Announced publication in the Journal of Vascular Anomalies highlighting the distinct biology and significant unmet need in microcystic lymphatic malformations, supporting early intervention and reinforcing the scientific rationale for QTORIN™ rapamycin as a targeted therapeutic approach.

•

Strengthened global intellectual property for QTORIN™ rapamycin with issuance of a European patent covering anhydrous topical compositions and methods of use, providing protection through 2038.

•

Phase 3 SELVA study results to be presented at the International Society for the Study of Vascular Anomalies World Congress 2026 on May 20, 2026, marking the first presentation of these data at a major medical meeting.

•

Pre-New Drug Application (NDA) meeting with the FDA granted; meeting expected in the second quarter of 2026.

•

NDA submission remains on track for the second half of 2026.

QTORIN™ rapamycin for cutaneous venous malformations (cutaneous VMs)

•

Phase 2 TOIVA study results to be presented at the International Society for the Study of Vascular Anomalies World Congress 2026 on May 20, 2026; additional data presentation planned at the 83rd Annual Meeting of the Society for Investigative Dermatology on May 12, 2026.

•

Submitted application for FDA Breakthrough Therapy Designation in the second quarter of 2026.

•

Phase 3 study initiation anticipated in the second half of 2026.

QTORIN™ rapamycin for clinically significant angiokeratomas

•

Dosed first patients in the Phase 2 LOTU trial, a single-arm, baseline-controlled clinical trial of QTORIN™ rapamycin administered topically once daily for the treatment of clinically significant angiokeratomas.

•

Topline results from LOTU are expected in the second half of 2027.

QTORIN™ pitavastatin for disseminated superficial actinic porokeratosis (DSAP)

•

Presented qualitative insights at the 2026 American Academy of Dermatology Annual Meeting from ten in-depth interviews highlighting the significant burden of porokeratosis, a rare genetic skin disease with no FDA-approved therapies. These

insights underscore its pre-cancerous nature and substantial physical, functional, and psychosocial impact, reinforcing the need for pathogenesis-directed therapies.

•

Phase 2 trial initiation expected in the second half of 2026.

QTORIN™ rapamycin and QTORIN™ platform expansion

•

Plan to announce the third product candidate from the QTORIN™ platform in a serious, rare disease with no FDA-approved therapies in the second half of 2026.

•

Plan to announce the fourth clinical indication for QTORIN™ rapamycin in the second half of 2026. The expansion of QTORIN™ rapamycin into additional indications is supported by comprehensive publications which highlight the broad potential of rapamycin in several difficult-to-treat, mTOR-driven skin diseases while advocating for targeted, topical approaches suited to improve tolerability and safety.

Recent Corporate Highlights

•

Closed an upsized and oversubscribed public offering of common stock generating $230.0 million in gross proceeds, including the full exercise of the underwriters’ option to purchase additional shares.

•

Strengthened Palvella’s leadership team with the appointments of Jennifer McDonough, Senior Vice President of Market Access & Patient Services, who previously contributed to the successful launch of VYJUVEK® at Krystal Biotech, and Kent Taylor as Senior Vice President of Sales, who previously led U.S. commercialization efforts for ZORYVE® at Arcutis Biotherapeutics and supported the launch of OPZELURA® at Incyte.

•

Expanded Palvella’s Board of Directors with the appointment of John D. Doux, M.D., M.B.A., a board-certified dermatologist and seasoned life sciences investor with deep expertise in rare skin diseases and biotechnology investing.

First Quarter 2026 Financial Results

•

Cash, cash equivalents, and short-term investments as of March 31, 2026 were $261.9 million, which reflects net proceeds of $215.8 million from a February 2026 equity financing.

•

Research and development expenses for the three months ended March 31, 2026 were $9.3 million, as compared to $4.1 million for the three months ended March 31, 2025. The increase was primarily due to increased spending for manufacturing activities and costs resulting from increased headcount and consulting services in 2026.

•

General and administrative expenses for the three months ended March 31, 2026 were $5.5 million, as compared to $3.8 million for the three months ended March 31, 2025. The increase was primarily due to increased headcount in 2026, as well as increased professional services related to operating as a publicly-traded company.

•

Net loss was $15.8 million, or $1.20 per basic and diluted share, for the three months ended March 31, 2026, as compared to net loss of $8.2 million, or $0.74 per basic and diluted share, for the three months ended March 31, 2025.

•

Shares outstanding were 15,738,543 as of May 1, 2026, including 14,342,844 shares of common stock and 1,394,761 common share equivalents assuming conversion of outstanding pre-funded warrants.

Conference Call Details

Palvella will host a conference call and live audiovisual webcast to discuss the Company's full year 2025 financial results and provide a corporate update at 8:30 a.m. ET today. To access the live webcast, including slides, please click here or visit the “Events & Presentations” section of Palvella’s website. To join the conference call by phone, dial 800-715-9871 (domestic) or +1 646-307-1963 (international) and provide Conference ID 9970701. Participants are encouraged to dial in approximately 15 minutes prior to the start of the call.

A replay of the webcast will be available approximately 2 hours after the conclusion of the call and archived for 90 days under the "Events & Presentations" section of the Company's website at www.palvellatx.com.

About Palvella Therapeutics

Founded and led by rare disease biotech veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare skin diseases and vascular malformations, many of which are lifelong in nature. Palvella’s lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently being developed for the treatment of microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas. Palvella’s second product candidate, QTORIN™ pitavastatin, is currently being developed for the treatment of disseminated superficial actinic porokeratosis. For more information, please visit www.palvellatx.com or follow Palvella on LinkedIn or X (formerly known as Twitter).

QTORIN™ rapamycin and QTORIN™ pitavastatin are for investigational use only and neither has been approved by the FDA or by any other regulatory agency for any indication.

Forward-Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (Securities Act)). These statements may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Palvella, as well as assumptions made by, and information currently available to, the management of Palvella. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding the expected

timing of the presentation of data from clinical trials, Palvella’s clinical development plans and related anticipated development milestones, Palvella’s plans to pursue Breakthrough Therapy Designation, Palvella’s plans to meet with regulatory authorities, Palvella’s expectations regarding the benefits of orphan drug designation and potential benefit of orphan drug exclusivity for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, Palvella’s cash, financial resources and expected runway, Palvella’s expectations regarding its programs, including QTORIN™ rapamycin and QTORIN™ pitavastatin, and its research-stage opportunities, including its expected therapeutic potential and market opportunity. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the ability to raise additional capital to finance operations; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, Palvella’s product candidates, including QTORIN™ rapamycin and QTORIN™ pitavastatin; the outcome of early clinical trials for Palvella’s product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; the fact that data and results from clinical studies may not necessarily be indicative of future results; Palvella’s limited experience in designing clinical trials and lack of experience in conducting clinical trials; Palvella’s limited experience in commercial manufacturing; the ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful than Palvella’s current product candidates; the substantial competition Palvella faces in discovering, developing, or commercializing products; the negative impacts of global events on operations, including ongoing and planned clinical trials and ongoing and planned preclinical studies; the ability to attract, hire, and retain skilled executive officers and employees; the ability of Palvella to protect its intellectual property and proprietary technologies; reliance on third parties, contract manufacturers, and contract research organizations; and the risks and uncertainties described in the filings made by Palvella with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that Palvella may face. Except as required by applicable law, Palvella does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.

Contact Information

Investors

Wesley H. Kaupinen

Founder and CEO, Palvella Therapeutics

wes.kaupinen@palvellatx.com

Media

Marcy Nanus

Managing Partner, Trilon Advisors LLC

mnanus@trilonadvisors.com

PALVELLA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share amounts)

Three Months Ended

March 31,

2026

2025

Operating expenses:

Research and development

9,334

4,074

General and administrative

5,521

3,797

Total operating expenses

14,855

7,871

Loss from operations

(14,855

)

(7,871

)

Total other income (expense), net

(912

)

(314

)

Net loss

(15,767

)

(8,185

)

Net loss per share of Common Stock — basic and diluted

(1.20

)

(0.74

)

Weighted-average shares used in computing net loss per share of Common Stock — basic and diluted

13,085,271

11,013,697

PALVELLA THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEET INFORMATION

(in thousands)

March 31,

December 31,

2026

2025

Assets

Cash and cash equivalents

206,394

57,982

Short-term investments

55,459

—

Other current assets

1,378

1,005

Total current assets

263,231

58,987

Non-current assets

528

572

Total assets

263,759

59,559

Liabilities and Stockholders' Equity

Current liabilities

9,115

11,344

Non-current liabilities

22,331

20,232

Total liabilities

31,446

31,576

Total stockholders' equity

232,313

27,983

Total liabilities and stockholders’ equity

263,759

59,559

EX-99.2

Filename: pvla-ex99_2.htm · Sequence: 3

First-in-disease therapies for patients with rare diseases Q1 2026 Financial Results & Corporate Update May 7, 2026

Forward Looking Statements This presentation contains forward-looking statements of Palvella Therapeutics, Inc. (“the Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained in this presentation include, but are not limited to, statements regarding the Company’s future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters, the Company’s current and prospective product candidates and any additional indications or platform candidates, the Company's planned research and development activities, the Company's planned clinical trials, including timing of receipt of data from the same, the planned regulatory framework for the Company's product candidates, the Company's expectations regarding the benefits of orphan drug designation and potential benefit of orphan drug exclusivity for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations, the Company's ability and the ability of third-party manufacturers the Company engages to optimize and scale manufacturing, the strength of the Company's intellectual property portfolio, and projections of the Company’s future ﬁnancial results and other metrics. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements. These forward-looking statements are based upon current estimates and assumptions of the Company and its management and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this presentation. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition, the ability of the Company to grow and manage growth, maintain relationships with suppliers and retain its management and key employees; the success, cost and timing of the Company’s product development activities, studies and clinical trials; changes in applicable laws or regulations; the possibility that the Company may be adversely affected by other economic, business or competitive factors; the Company’s estimates of expenses and proﬁtability; the evolution of the markets in which the Company competes; the ability of the Company to implement its strategic initiatives and continue to innovate its existing products; and the ability of the Company to defend its intellectual property. Nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company undertakes no duty to update these forward-looking statements. Industry and Market Data The Company may from time to time provide estimates, projections and other information concerning its industry, the general business environment, and the markets for certain conditions, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this presentation. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate. Trademarks This Presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this Presentation may be listed without the TM, SM © or ® symbols, but the Company will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights.

Q1 2026 Achievements Position Company for First Potential Approval and Launch of QTORIN™ Rapamycin $230mm raised in gross proceeds in upsized equity financing Microcystic Lymphatic Malformations: Advancing Towards Potential 1H 2027 Approval Phase 3 results exceeded upside case profile NDA remains on track for 2H 2026; pre-NDA meeting granted for Q2 2026 Exceptional veteran commercial leadership recruited; launch planning accelerating Phase 3 initiation on track Cutaneous VMs Angiokeratomas Accelerated towards first patients dosed ahead of schedule DSAP Review published in Clinical and Experimental Dermatology >40 patient inbounds for clinical trial

597 Rare Skin Diseases Often serious and chronically debilitating Over 98% Have No Approved Therapies1 Lower industry innovation and investment compared to other therapeutic areas (e.g., oncology, neurology, pulmonary) Note: John Doux, M.D. is a member of the Palvella Board of Directors. 1. Licholai G., Rare Dermatology Orphan Disease Drug Development Opportunities & Challenges, Presented at Dermatology Summit, Jan 2019. “We have begun to see interest from investors and companies in developing treatments for a rare disease such as epidermolysis bullosa, but there are many other diseases within dermatology that remain unaddressed” John Doux, M.D., Barriers and Opportunities Across the Development Divide, The Society of Investigative Dermatology, 2015 Palvella: Vision and Leadership in Treating Serious, Rare Skin Diseases

Palvella: Driving the Next Wave of Innovation in Under-appreciated Rare Skin Diseases Diagnosed U.S. Prevalence1 30k+ Microcystic LMs 75k+ Cutaneous VMs 50k+ Clinically Significant Angiokeratomas 50k+ Disseminated Superficial Actinic Porokeratosis 1. Clarity Pharma, Trinity Life Sciences, MedaCorp, and ZS Associates. 2. MedaCorp market research. Market Research: % Physicians Who Would Consider QTORIN™ as First-line Therapy2 >80% across four indications None # of FDA-approved Therapies

Attracting proven commercial talents Positive Phase 3 data in microcystic LMs and positive Phase 2 data in cutaneous VMs Positive Clinical Data and Upsized Equity Financing Enable Accelerated U.S. Launch Planning $230 million Gross proceeds in upsized equity financing Engaging top 400 high-volume centers, including VACs* Jen McDonough SVP Market Access Prev. Krystal Biotech Kent Taylor SVP Sales Prev. Arcutis Targeting higher end of range for field sales force (30-40 reps) with plans to hire prior to PDUFA 1 2 Two MSLs hired, with plans for additional hires, to drive disease state awareness *VACs = vascular anomaly centers.

QTORIN™ Rapamycin: >$1bn U.S. Peak Sales Potential in Microcystic LMs QTORIN™ Rapamycin Potential to Achieve >$1bn Peak Sales >30k diagnosed U.S. patients, with concentration in vascular anomaly centers Microcystic Lymphatic Malformations Annual ~$100k-$200k pricing range per patient Recent field checks, annual incidence estimates, published claims analysis Supported by Phase 3 SELVA data, payor testing, analogues QTORIN™ 3.9% rapamycin anhydrous gel QTORIN™ 3.9% rapamycin anhydrous gel is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency. The safety or efficacy has not been established for any use.

OUR PLATFORM QTORIN™

QTORIN™: Repeatable New Product Development Engine PARADIGM SHIFT towards targeted and well-tolerated delivery to the dermis BROAD PLATFORM CAPABILITY across diverse range of molecules NEW LONG-DURATION IP opportunity with each product candidate Rapid pipeline expansion with capital- and time-efficient QTORIN™ programs

Rare Disease Pipeline Overview

SELVA: Additional Analyses Support Clinical Meaningfulness IGA: +3 “ It doesn’t bleed anymore and it’s really clear... It just looks like my normal skin. …it doesn't leak constantly like it used to. KEY INSIGHTS “ Week 24 [The lesion] became closer to the color of my skin tone before it fully went away A pre-specified embedded patient interview sub-study provided qualitative evidence supporting the clinical meaningfulness of the improvements observed in SELVA Patient findings strengthen overall risk/benefit narrative for planned NDA submission Interviews reinforced that SELVA endpoints captured meaningful changes to patients’ lives Improvements in disease burden were consistently reported by patients

Two prospective studies with statistical significance, with 95% of patients improving on mLM-IGA at Week 24 in SELVA Seeking traditional approval based on clinical endpoints (not biomarkers for accelerated approval) Planned 505(b)(2) submission: leveraging FDA’s prior findings for rapamycin to streamline review process Planned 505(b)(2)-Enabled NDA Submission Pre-NDA meeting granted by FDA, with meeting expected Q2 2026 Real-world studies from off-label rapamycin use as supportive evidence Supported by FDA Orphan Products Grant: Two tranches of non-dilutive funding received

Strong Medical Affairs Presence with Sponsorship and Presentations at Key Medical Congresses Platinum Sponsor at ISSVA World Congress (May 19-22, 2026) Title: QTORIN™ 3.9% Rapamycin Anhydrous Gel: Statistically Significant, Clinically Meaningful Improvement in Microcystic Lymphatic Malformations (Phase 3 SELVA Study) and Cutaneous Venous Malformations (Phase 2 TOIVA Study) Date/Time: Wednesday, May 20, 2026 at 4:30pm ET LATE-BREAKER PRESENTATION SCIENTIFIC SYMPOSIUM Title: Clinical Development in Rare Cutaneous Vascular Disorders: Lessons Learned from SELVA and TOIVA Trials Date/Time: Thursday, May 21, 2026 at 12:30pm ET BEYOND mLM LOUNGE Attendees can participate in discussions on mLM and sign up to receive educational resources and communications for both themselves and their patients Planned Presentations at Additional Medical Congresses: Epidermal Differentiation Disorders Symposium (Platinum Sponsor) May 12, 2026, Chicago, IL Jul 22-25, 2026Minneapolis, MN Oct 15-17, 2026 Alexandria, VA JAMES TREAT, MD Professor of Clinical Pediatrics and Dermatology, CHOP

Cutaneous Venous Malformations:73% of Patients Improved in Phase 2 No FDA-approved therapies Fast Track Designation Granted Breakthrough Therapy Designation application submitted Pipeline-in-a-product: sNDA planned > 75k patients ESTIMATED DIAGNOSED IN THE U.S. POTENTIAL TO BE FIRST FDA-APPROVED THERAPY Why this fits Palvella’s strategy: Serious, rare, mTOR-driven Meaningful overlap with microcystic LM physicians at centers of excellence On track for Phase 3 trial initiation in 2H 2026 Additional findings from Phase 2 TOIVA study to be presented at ISSVA World Congress later this month Market research (n=50 physicians): 86% would consider QTORIN™ rapamycin as first-line therapy for cutaneous VMs

Clinically Significant Angiokeratomas: Superficial Lymphatic Malformations Lymphatic origin1,5 Superficial dermal location3,5 Clinically impactful, causing bleeding, functional impairment, and risk of infection4,5 Microcystic LMs Angiokeratomas Scientific rationale and real-world evidence supporting targeted therapy with rapamycin2,5 P P P P P P P P Shared Clinical Features between Clinically Significant Angiokeratomas and Microcystic LMs 1. Trindade F, et al. Am J Dermatopathol, Sep 30, 2014. 2. Bell KA, et al. JAAD Case Reports, Nov 30, 2020; Camacho I, et al. Dermatologic Therapy, Jun 27, 2020; Moeineddin F, et al. Clinical Case Reports, May 31, 2024; Farajzadeh S, et al. Indian J Dermatol Venereol Leprol, Jun 20, 2023; Fernández Ginés Fd, et al. Eur J Hosp Pharm, Feb 28, 2018; Kang Y, et al. J Korean Association of Oral Maxillofacial Surgery July 12, 2014. 3. Trindade F, et al. Am J Dermatopathol, Sep 30, 2014. 4. Philip C, et al. Dermatological Therapeutics March 31, 2020; Hobbs et al, Journal of Dermatology Surg Onco, 1987. 5. Teng et al, Lymphatic Research and Biology, 2022.

> 50k patients ESTIMATED DIAGNOSED IN THE U.S. Clinically Significant Angiokeratomas: Superficial Lymphatic Malformations FIRST PATIENTS DOSED IN PHASE 2 TRIAL MAY 2026 A type of isolated lymphatic malformation: direct scientific adjacency to microcystic LMs FDA granted Fast Track Designation in Dec 2025 Phase 2 LOTU study is a single-arm, baseline-controlled clinical trial evaluating QTORIN™ rapamycin applied topically once daily Enrolling up to 15 patients Topline results are expected in 2H 2027 Market research (n=50 physicians): 96% would incorporate QTORIN™ rapamycin into their practice No FDA-approved therapies Fast Track Designation Granted Pipeline-in-a-product: sNDA planned

> 50k patients ESTIMATED DIAGNOSED IN THE U.S. Disseminated Superficial Actinic Porokeratosis (DSAP): Chronic, Pre-Cancerous, and Progressive No FDA-approved therapies Current options: Laser, surgery, and off-label topical chemo agents & mevalonate pathway inhibitors QTORIN™ PITAVASTATIN POTENTIAL TO BE FIRST FDA-APPROVED THERAPY AND STANDARD OF CARE First pathogenesis-directed therapy targeting the casual mevalonate pathway Phase 2 initiation on track for 2H 2026 Strong patient interest for planned Phase 2 study; over 40 inbound patient inquiries, including: “I tried several unsuccessful treatments. This is a disfiguring… potentially cancerous condition. After years of waiting, the prospect of a successful treatment is exciting. If I can be part of the solution by participating in a clinical trial, count me in.” “Having tried just about everything to treat this rare disorder, I am EXCEPTIONALLY interested in your clinical trial…I am desperate for any treatment”

QTORIN™ Rapamycin Rare Serious Strong Scientific & Biologic Rationale Commercially Attractive No FDA-approved Therapies Chronic, extensive lesions, malignant transformation >50k U.S. patients Mutations in mevalonate pathway lead to accumulation of toxic intermediates None Microcystic LMs, Cutaneous VMs, Clinically Significant Angiokeratomas DSAP Significant unmet medical need Multi-billion dollar U.S. TAM1 Optimizing likelihood of clinical success Opportunity to be first-in-disease and SOC Published Case Studies & Off-label Use of API Multiple published case studies + use in academic centers P P P P P P Based on internal and third-party estimates. QTORIN™ Pitavastatin Disseminated Superficial Actinic Porokeratosis (DSAP): Aligned With Palvella’s Pipeline Strategy

Finance & Upcoming Catalysts

Well-Capitalized with High-Quality Investor Participation in $230mm Oversubscribed Feb. 2026 Financing Following Positive SELVA Data Potential to Fund Through: QTORIN™ + 505(b)(2) + rare disease focus offers potential for attractive ROI NDA filing, FDA approval, and, if approved, U.S. launch for QTORIN™ rapamycin in microcystic LMs NDA filing for QTORIN™ rapamycin in cutaneous VMs Multiple Phase 2 data readouts from pipeline programs $262 million 3/31/26 cash

Microcystic Lymphatic Malformations: NDA Submission on Track for 2H 2026 with Anticipated U.S. Commercialization in 1H 2027 QTORIN™ 3.9% rapamycin anhydrous gel is for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency. The safety or efficacy has not been established for any use. Microcystic Lymphatic Malformations 1 Positive Phase 3 SELVA data In-person pre-NDA meeting granted by FDA, to occur in Q2 2026 Findings to be presented at ISSVA World Congress, May 2026 NDA submission on track for 2H 2026 Potential FDA approval and U.S. launch 1H 2027

Multiple High-Impact Pipeline Milestones in 2026: Density of Catalyst Creation Driven by QTORIN™ QTORIN™ 3.9% rapamycin anhydrous gel and QTORIN™ pitavastatin are for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency. The safety or efficacy has not been established for any use. Clinically Significant Angiokeratomas 3 Fast Track Designated Phase 2 initiated May 2026, ahead of schedule Phase 2 data expected 2H 2027 Disseminated Superficial Actinic Porokeratosis 4 QTORIN™ pitavastatin formulation developed, IP filed Phase 2 initiation expected 2H 2026 Cutaneous Venous Malformations 2 Positive Phase 2 data BTD application submitted Q2 2026 P3 initiation expected 2H 2026

Multiple High-Impact Pipeline Milestones in 2026: Density of Catalyst Creation Driven by QTORIN™ QTORIN™ 3.9% rapamycin anhydrous gel and QTORIN™ pitavastatin are for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency. The safety or efficacy has not been established for any use. Clinically Significant Angiokeratomas 3 Fast Track Designated Phase 2 initiated May 2026, ahead of schedule Phase 2 data expected 2H 2027 Disseminated Superficial Actinic Porokeratosis 4 QTORIN™ pitavastatin formulation developed, IP filed Phase 2 initiation expected 2H 2026 Announcement expected 2H 2026 Potential pipeline-in-a-product QTORIN™ Third Program 5 DAVID OSBORNE, PhD Chief Innovation Officer Cutaneous Venous Malformations 2 Positive Phase 2 data BTD application submitted Q2 2026 P3 initiation expected 2H 2026

Multiple High-Impact Pipeline Milestones in 2026: Density of Catalyst Creation Driven by QTORIN™ QTORIN™ 3.9% rapamycin anhydrous gel and QTORIN™ pitavastatin are for investigational use only and has not been approved or cleared by the FDA or by any other regulatory agency. The safety or efficacy has not been established for any use. Clinically Significant Angiokeratomas 3 Fast Track Designated Phase 2 initiated May 2026, ahead of schedule Phase 2 data expected 2H 2027 Disseminated Superficial Actinic Porokeratosis 4 QTORIN™ pitavastatin formulation developed, IP filed Phase 2 initiation expected 2H 2026 Announcement expected 2H 2026 Potential pipeline-in-a-product QTORIN™ Third Program 5 DAVID OSBORNE, PhD Chief Innovation Officer QTORIN™ rapamycin fourth indication announcement expected 2H 2026 QTORIN™ Rapamycin Fourth Indication 6 Cutaneous Venous Malformations 2 Positive Phase 2 data BTD application submitted Q2 2026 P3 initiation expected 2H 2026

Closing Remarks

What Makes Palvella Stand Apart Repeatably unlocking multi-billion dollar market opportunities in previously untreated orphan diseases First-in-Disease Focus Rare Diseases with Clear Disease Biology Leveraging Existing Human Proof-of-Concept and Safety Data Innovative QTORIN™ Platform: Durable IP Generation Veteran team executing rare disease model designed to reduce time and capital to FDA approval 1 2 3 4

PALVELLA (pɑlʋelːɑ, Finnish): TO SERVE Building the leading rare disease biopharma company focused on developing and commercializing first-in-disease therapies for serious, rare skin diseases and vascular malformations

Striving to be first for rare disease patients Thank You

GRAPHIC

Filename: img6060170_0.jpg · Sequence: 4

Binary file (34152 bytes)

Download img6060170_0.jpg

GRAPHIC

Filename: pvla-ex99_2s1.jpg · Sequence: 5

Binary file (247399 bytes)

Download pvla-ex99_2s1.jpg

GRAPHIC

Filename: pvla-ex99_2s2.jpg · Sequence: 6

Binary file (869596 bytes)

Download pvla-ex99_2s2.jpg

GRAPHIC

Filename: pvla-ex99_2s3.jpg · Sequence: 7

Binary file (390515 bytes)

Download pvla-ex99_2s3.jpg

GRAPHIC

Filename: pvla-ex99_2s4.jpg · Sequence: 8

Binary file (369156 bytes)

Download pvla-ex99_2s4.jpg

GRAPHIC

Filename: pvla-ex99_2s5.jpg · Sequence: 9

Binary file (282263 bytes)

Download pvla-ex99_2s5.jpg

GRAPHIC

Filename: pvla-ex99_2s6.jpg · Sequence: 10

Binary file (368855 bytes)

Download pvla-ex99_2s6.jpg

GRAPHIC

Filename: pvla-ex99_2s7.jpg · Sequence: 11

Binary file (331670 bytes)

Download pvla-ex99_2s7.jpg

GRAPHIC

Filename: pvla-ex99_2s8.jpg · Sequence: 12

Binary file (139770 bytes)

Download pvla-ex99_2s8.jpg

GRAPHIC

Filename: pvla-ex99_2s9.jpg · Sequence: 13

Binary file (343665 bytes)

Download pvla-ex99_2s9.jpg

GRAPHIC

Filename: pvla-ex99_2s10.jpg · Sequence: 14

Binary file (154329 bytes)

Download pvla-ex99_2s10.jpg

GRAPHIC

Filename: pvla-ex99_2s11.jpg · Sequence: 15

Binary file (366959 bytes)

Download pvla-ex99_2s11.jpg

GRAPHIC

Filename: pvla-ex99_2s12.jpg · Sequence: 16

Binary file (355325 bytes)

Download pvla-ex99_2s12.jpg

GRAPHIC

Filename: pvla-ex99_2s13.jpg · Sequence: 17

Binary file (453388 bytes)

Download pvla-ex99_2s13.jpg

GRAPHIC

Filename: pvla-ex99_2s14.jpg · Sequence: 18

Binary file (427468 bytes)

Download pvla-ex99_2s14.jpg

GRAPHIC

Filename: pvla-ex99_2s15.jpg · Sequence: 19

Binary file (400128 bytes)

Download pvla-ex99_2s15.jpg

GRAPHIC

Filename: pvla-ex99_2s16.jpg · Sequence: 20

Binary file (408427 bytes)

Download pvla-ex99_2s16.jpg

GRAPHIC

Filename: pvla-ex99_2s17.jpg · Sequence: 21

Binary file (491549 bytes)

Download pvla-ex99_2s17.jpg

GRAPHIC

Filename: pvla-ex99_2s18.jpg · Sequence: 22

Binary file (378820 bytes)

Download pvla-ex99_2s18.jpg

GRAPHIC

Filename: pvla-ex99_2s19.jpg · Sequence: 23

Binary file (153427 bytes)

Download pvla-ex99_2s19.jpg

GRAPHIC

Filename: pvla-ex99_2s20.jpg · Sequence: 24

Binary file (343099 bytes)

Download pvla-ex99_2s20.jpg

GRAPHIC

Filename: pvla-ex99_2s21.jpg · Sequence: 25

Binary file (357331 bytes)

Download pvla-ex99_2s21.jpg

GRAPHIC

Filename: pvla-ex99_2s22.jpg · Sequence: 26

Binary file (225587 bytes)

Download pvla-ex99_2s22.jpg

GRAPHIC

Filename: pvla-ex99_2s23.jpg · Sequence: 27

Binary file (275786 bytes)

Download pvla-ex99_2s23.jpg

GRAPHIC

Filename: pvla-ex99_2s24.jpg · Sequence: 28

Binary file (327194 bytes)

Download pvla-ex99_2s24.jpg

GRAPHIC

Filename: pvla-ex99_2s25.jpg · Sequence: 29

Binary file (378936 bytes)

Download pvla-ex99_2s25.jpg

GRAPHIC

Filename: pvla-ex99_2s26.jpg · Sequence: 30

Binary file (415098 bytes)

Download pvla-ex99_2s26.jpg

GRAPHIC

Filename: pvla-ex99_2s27.jpg · Sequence: 31

Binary file (140681 bytes)

Download pvla-ex99_2s27.jpg

GRAPHIC

Filename: pvla-ex99_2s28.jpg · Sequence: 32

Binary file (287338 bytes)

Download pvla-ex99_2s28.jpg

GRAPHIC

Filename: pvla-ex99_2s29.jpg · Sequence: 33

Binary file (393917 bytes)

Download pvla-ex99_2s29.jpg

GRAPHIC

Filename: pvla-ex99_2s30.jpg · Sequence: 34

Binary file (157098 bytes)

Download pvla-ex99_2s30.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 37

v3.26.1

Cover

May 07, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 07, 2026

Entity File Number

001-37471

Entity Registrant Name

Palvella Therapeutics, Inc.

Entity Central Index Key

0001583648

Entity Tax Identification Number

30-0784346

Entity Incorporation, State or Country Code

Entity Address, Address Line One

353 W. Lancaster Ave

Entity Address, Address Line Two

Suite 200

Entity Address, City or Town

Wayne

Entity Address, State or Province

Entity Address, Postal Zip Code

19087

City Area Code

484

Local Phone Number

253-1461

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.001 par value per share

Trading Symbol

PVLA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration